Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Abstract Aims Sodium–glucose co‐transporter 2 ( SGLT2 ) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have ... View More